摘要
目的探讨乌梅丸对Hp阳性糖尿病胃轻瘫患者的疗效。方法选择Hp阳性糖尿病胃轻瘫患者90例,随机分为3组(乌梅丸组、红霉素组、莫沙必利组),在控制血糖的基础上,3组分别给予乌梅丸、红霉素、莫沙必利口服,疗程30d,观察治疗前后症状及14C呼气试验值。结果乌梅丸组治疗后总有效率明显优于红霉素、莫沙必利组(P<0.05)。治疗后乌梅组14C呼气试验(14C-UBT)值下降,与治疗前比较差异有统计学意义(P<0.05);治疗后与莫沙必利组比较有差异有统计学意义(P<0.05),与红霉素组比较差异无统计学意义(P>0.05)。结论乌梅丸能降低Hp阳性糖尿病胃轻瘫患者Hp感染水平,对糖尿病胃轻瘫患者有较好的疗效。
Objective To investigate the clinical effect of Wumei Pill in treatment of diabetic gastroparesis （DGP） patients with positive Hp. Methods Ninety DGP patients with positive Hp were selected and divided into three groups： Wumei Pill group （n = 30）, erythromycin group （n = 30）, mosapride group （n = 30）. The patients were treated with corresponding drugs for 30 days. And three groups were taken pre-and post-treatment for measuring symptoms and 14C-urea breath tests. Results The clinical effect in Wumei Pill group was significantly higher than that in other two groups after treatment （P 〈 0.05）. The levels of 14C-urea breathe tests dropped in three groups. The levels of 14C-urea breath tests in Wumei Pill group were significantly lower than pre-treatment, and it was lower than that in mosapride group after treatment （P 〈 0.05）. Conclusion Wumei Pill can reduce the clinical symptoms and levels of 14C-urea breathe tests significantly.
出处
《中国当代医药》
2013年第5期117-118,120,共3页
China Modern Medicine
